Jaguar Health FY2025 net loss widens to $53.6M; enters Future Pak deal for non-dilutive capital; Nasdaq appeal pending

Jaguar Health, Inc.

Net revenue FY2025 $11.5M (-1.5% YoY); Q4 2025 net revenue $3.2M (+5% QoQ, -8% YoY).
Net loss attributable to common stockholders FY2025 $53.6M vs $38.5M; loss from operations $45.9M.
Mytesi prescription volume down 3.7% in 2025 vs 2024; Q4 2025 down 12.2% YoY.
Entered license agreement with Future Pak Jan 2026: $16M up-front non-dilutive capital, $2M additional upon conditions; FP to commercialize Mytesi and Canalevia-CA1.
Received Nasdaq noncompliance notice; appeal hearing April 7, 2026; delisting stayed pending decision.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Jaguar Health, Inc. reported year ended December 31, 2025 results: revenue $11.5 million, net income $53.6 million net loss, EPS ($24.27) per share.

Period: year ended December 31, 2025
Revenue: $11.5 million
Net income: $53.6 million net loss
EPS: ($24.27) per share
Result: reported results

Exact text from the filing

the total net revenue in the fourth quarter of 2024, which totaled approximately $3.5 million. • In 2025, approximately $11.2 million out of the Company’s total net revenue of $11.5 million was generated by sales of Mytesi and Canalevia-CA1. Under the terms of the license agreement Jaguar entered with Future Pak (“FP”) in January 2026, FP will be responsible for all

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-144604

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.